Regulation-Driven Variation in Utilization and Cost of B-Cell Depleting Therapies for Multiple Sclerosis: A Cross-National Study
The AI brief for this paper is being written. Open it in JClub to read the paper with the brief as soon as it lands.
Read the brief in JClub →